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Abstract
Background: Fragile X syndrome (FXS), the leading cause of inherited mental retardation, is due to expansion and
methylation of a CGG sequence in the FMR1 gene, which result in its silencing and consequent absence of FMRP
protein. This absence causes loss of repression of metabotropic glutamate receptor 5 (mGluR5)-mediated pathways
resulting in the behavioral and cognitive impairments associated with FXS. In a randomized, double-blind trial it
was recently demonstrated a beneficial effect of AFQ056, a selective inhibitor of metabotrobic glutamate receptor
type 5 (mGluR5), on fully methylated FXS patients respect to partially methylated FXS ones.
Methods: To determine whether AFQ056 may have secondary effects on the methylation and transcription of
FMR1, here we treated three FXS lymphoblastoid cell lines and one normal control male line. A quantitative RT-PCR
was performed to assess transcriptional reactivation of the FMR1 gene. To assess the methylation status of the
FMR1 gene promoter it was carried out a bisulphite sequencing analysis.
Results: Both FMR1-mRNA levels and DNA methylation were unmodified with respect to untreated controls.
Conclusions: These results demonstrate that the AFQ056 effect on fully methylated FXS patients is not due to a
secondary effect on DNA methylation and consequent transcriptional activation of FMR1.
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Background
The fragile X syndrome (FXS, MIM #300624), the most
common cause of inherited mental retardation, is due to
the amplification (> 200 repeats) of a sequence of CGG
triplets in the 5’ UTR of the FMR1 gene, followed by
methylation of cytosines, including those of the promo-
ter upstream [1]. Although the coding region of the
gene remains intact, the two changes, one structural and
one epigenetic, lead to transcriptional silencing, and
consequent absence of the FMRP protein, responsible
for the manifestations of the syndrome. FMRP is an
RNA-binding protein, which inhibits the translation of
messenger RNAs (mRNAs), especially within post-
synaptic vesicles of the dendritic spines of hippocampal
neurons [2]. It has been demonstrated that the absence
of FMRP causes an upregulation of metabotropic
glutamate receptors 5 (mGluR5)-mediated signalling
pathways, which is the probable cause of the behavioural
and cognitive impairments observed in FXS patients [3].
In FXS animal models it was demonstrated that many
aspects of the phenotype (behavioural abnormalities,
learning deficit, altered dendritic spines, macroorchid-
ism) may be due to excessive mGluR5 signalling. Indeed,
crossing Fmr1 KO mice with heterozygous Grm5 KO
mice, expressing reduced amounts of glutamate recep-
tors, rescues many of the FXS phenotypes, except for
macroorchidism [4]. Consequently, the use of mGluR5
antagonists may represent an effective treatment for
many FXS symptoms. The use of 2-methyl-6-(pheny-
lethynyl)-pyridine (MPEP), a prototypic mGluR5 inhibi-
tor, rescues hyperactivity and audiogenic seizures in
Fmr1 KO [5]. Recently, in a study performed on Fmr1
KO mice, AFQ056, a subtype-selective inhibitor of
mGluR5, rescued the inhibition of the startle response
after a prepulse, while cultured hippocampal neurons
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was recently performed to assess the safety and toler-
ability of AFQ056 in FXS patients, as well as its possible
beneficial effect on the behavioural phenotype [7]. This
randomized, double-blind, placebo-controlled, cross-
over study was performed on 30 FXS male subjects.
Seven of these, who were carriers of a fully methylated
FMR1 mutation, with no detectable production of
FMR1-mRNA, showed a significant improvement of
their behaviour, as measured with the ABC-C scale,
after treatment with AFQ056, compared to the placebo-
treated controls. No response was detected in FXS sub-
jects who carried a partially methylated FMR1 full muta-
tion. This unanticipated finding begs the question
whether AFQ056 may have an indirect or secondary
effect on methylation of the mutant FMR1 gene and,
consequently, on its transcription.
To answer this question we studied the effect of
AFQ056 on FMR1 promoter methylation and mRNA
production in three FXS lymphoblastoid cell lines with
different degrees of DNA methylation (two fully and
one partially methylated) and in one normal control
line. No demethylation was induced by the treatment
with AFQ056 and the levels of FMR1-mRNA remained
unmodified. These findings support the conclusion that
the AFQ056 effect observed in fully methylated patients
i sn o td u et oac h a n g ei nt h em e t h y l a t i o no nt h eFMR1
g e n e ,b u tm a yr e s u l tf r o mt h ei n t e r a c t i o no fA F Q 0 5 6
with other, yet unknown, target proteins.
Methods
Lymphoblastoid cell lines were established by Epstein-
Barr virus (EBV) transformation from peripheral blood
lymphocytes of a normal control male (WT) and three
FXS males, with CGG expansion of 250 (E3), 450 (S1)
and 100-960 (MP, premutation/full mutation mosaic)
repeats, respectively. Lymphoblasts were grown in
RPMI1640 medium supplemented with 10% fetal bovine
serum, 2.5% of L-glutamine and penicillin/streptomycin
at 37°C with 5% CO2. Treatments were done in T75 flask
containing approximately 20 × 10
6 cells in a volume of
20 ml. The effect of a single treatment with AFQ056
(Novartis) was assessed at various times and concentra-
tions. The drug was added daily at either 1, 10, 100 or
1,000 μM concentration and cells were harvested to
extract RNA and DNA after 3 or 8 days from the begin-
ning of the treatment. Control cultures were sham-trea-
ted with the drug diluent. As positive controls for the
FMR1 reactivation, parallel cultures were also treated
with 1 μM 5-aza-2-doxycytydine (5-azadC) (Sigma-
Aldrich). Cell viability was assessed after 8 days of treat-
ment using NucleoCounter
® (Chemometec, Denmark).
Total RNA from treated and untreated cell lines was
extracted with the single-step acid phenol method using
Trizol (Invitrogen), reverse-transcribed to cDNA by
MoMLV-RT (Invitrogen) and used for quantitative
fluorescent RT-PCR, using an ABI 7900 HT (Applied
Biosystems) [8].
Bisulphite sequencing of the 52 CpG sites of the
FMR1 promoter region was performed as previously
described [8]. A total of 9 clones were sequenced from
WT, E3 and MP cell lines before and after treatment
with AFQ056.
Results
The AFQ056 treatment was performed on WT and
three FXS lymphoblastoid cell lines. No FMR1-mRNA
increase was observed after treatment with AFQ056 in
any of the four cell lines, with respect to the untreated
controls. All results are summarized in Figure 1. The
WT cell line was used to establish the basal level of
FMR1 gene transcription. The partial decrease in FMR1
transcription observed in WT at 1 mM AFQ056 after 3
and 8 days of treatment (panel A) was due at least in
part to cell mortality. Actually at 8 days post-treatment
the cell viability had decreased from 20 to 12 × 10
6
cells. A second reason is the physiological fluctuations
in FMR1 gene transcription previously observed [9]. All
cell lines were also treated with [1 μM] 5-azadC for 3
and 8 days, respectively, to test the efficiency of tran-
scriptional reactivation (positive control for FMR1 gene
reactivation). The 5-azadC showed a mean FMR1 reacti-
vation of 10% after 3 days and of 25% after 8 days for
E3 and S1 cell lines, while in the WT cell line no signifi-
cant increase was observed, in accordance with previous
results [8]. The MP (size and methylation mosaic) cell
line displayed higher levels of FMR1 reactivation (20%
and 32% after 3 and 8 days, respectively) according with
the residual transcription of the gene in these cells. This
latter cell line was derived from an FXS boy and did not
show any residual translation on Western blot (data not
shown).
In spite of the lack of effect of AFQ056 on FMR1
transcript, we went on to analyze DNA methylation of
the 52 cytosines constituting the CpG island of the
FMR1 promoter region. Bisulphite sequencing was per-
formed on 9 clones (cells) of untreated WT and on 4
clones each of WT after 3 and 8 days of treatment with
1 mM AFQ056. A total of 9 clones were sequenced for
FXS lines E3 and MP and 9 clones for the same FXS
cell lines after treatment. As expected, the promoter of
the untreated and treated WT cells was entirely
unmethylated, while in the untreated FXS cell lines it
was fully methylated, with the exception of few clones
completely unmethylated in the MP mosaic cell line.
AFQ056 treatment had no effect on methylation, leaving
the promoter as methylated as in the untreated controls
both WT and FXS (Figure 2).
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A link between the neurological and behavioural FXS
phenotype, due to absence of FMRP, and the upregula-
tion of mGluR5-mediated activities at dendritic synapses
was proposed by the so-called mGluR theory [3]. Both
FXS patients and Fmr1 KO mice show elongated den-
dritic spines and enhanced mGluR5-mediated long term
depression (LTD) due to a perturbation of the mGluR5
signalling [4].
The observations led to consider the possible use of
mGluR5 antagonists to treat FXS symptoms. One of the
first compounds to be tested was MPEP, as already dis-
cussed [5]. A similar effect was obtained with fenobam,
another mGluR5 inhibitor [10]. Fenobam was originally
used as an anxiolytic agent, even though at that time its
molecular target in the brain was not known. Later on,
it was discovered that fenobam is a potent and selective
negative allosteric modulator of mGluR5 like MPEP, but
with a different chemical structure [11]. A small open-
label, single-dose trial of fenobam was conducted to
provide an initial evaluation of safety and pharmacoki-
netics in FXS adults, without any significant adverse
effects and with a few beneficial clinical effects [12].
More recently encouraging results were obtained by
treating Fmr1 KO mice with AFQ056, a subtype-
selective inhibitor of mGluR5, capable of rescuing the
prepulse inhibition deficit, as well as the dendritic spine
phenotype [6]. This compound had previously been
used in a clinical trial of Parkinson disease patients with
levodopa-induced dyskinesia, demonstrating antidyski-
netic effect without changing the antiparkinsonian
effects of dopaminergic therapy [13]. Based on evidence
of safety and potential clinical efficacy, AFQ056 was
used in a randomized, double-blind, two-treatment,
two-period, crossover trial of 30 FXS patients aged 18-
35 years [7]. In the primary outcome measure (ABC-C
score) of this study no statistically significant differences
were observed among the treated and untreated groups.
However, a secondary exploratory analysis suggested
that the response to AFQ056 may be predicted by the
methylation status of the FMR1 promoter: subjects with
a fully methylated FMR1 promoter showed statistically
significant improvement in their behaviour, while car-
riers of a partially methylated promoter did not. These
findings demonstrated that AFQ056 may alleviate
stereotypic behaviour, hyperactivity, inappropriate
speech and restricted interests and also improve autistic
behaviour in FXS subjects whose FMR1 promoter is
fully methylated. Our present in vitro study of AFQ056
on three FXS lymphoblastoid cell lines with different
Figure 1 Quantitative estimate of FMR1-mRNA levels in one WT (panel A) and three FXS (panels B-D) cell lines treated for 3 and 8
days with 1, 10, 100 and 1,000 μM AFQ056, respectively. Real-time fluorescent RT-PCR was normalized to a WT untreated cell line. The
same cell lines were also treated with [1 μM] 5-azadC to test the efficiency of transcriptional reactivation and also with the drug diluent (mock).
The data are expressed as fractions of the value observed in the untreated WT, arbitrarily set at 1.
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strates that the phenotypic improvement observed in
the fully methylated patients is not due to an effect on
methylation induced by this drug on the promoter
region. Treatment of FXS cell lines with AFQ056 did
not cause either an increase in the FMR1 transcription
or demethylation of the FMR1 promoter. These findings
were consistently reproducible in three different FXS
cell lines. The partial decreased transcription observed
in WT cell treated with 1 mM of AFQ056 was probably
not due to an effect on DNA methylation, but rather to
physiological variations in gene transcription and to cell
mortality, as indicated by cell count. Clearly, we are
aware that results obtained in lymphoblastoid cells may
not necessarily reflect the status of neuronal cells,
whose behaviour is central to the pathophysiology of
FXS.
Conclusion
Given the results obtained in this study, one could spec-
ulate that full methylation of the FMR1 promoter may
reflect the activity, or lack thereof, of other proteins
interacting with the mGluR5 signalling pathway, thus
favouring the beneficial effect of AFQ056 in this subpo-
pulation of FXS patients. An alternative explanation
could be that only in the fully methylated patients the
mGluR5-mediated signalling is sufficiently high to make
the effect of AFQ056 clinically detectable, while this
would not be the case in partially methylated patients
where the mGluR5 signalling is not so high, due to resi-
dual presence of the FMR1 protein.
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